Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Total Liabilities (2021 - 2026)

Centessa Pharmaceuticals has reported Total Liabilities over the past 5 years, most recently at $160.6 million for Q4 2025.

  • Quarterly Total Liabilities fell 8.34% to $160.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $160.6 million through Dec 2025, down 8.34% year-over-year, with the annual reading at $160.6 million for FY2025, 8.34% down from the prior year.
  • Total Liabilities was $160.6 million for Q4 2025 at Centessa Pharmaceuticals, up from $146.7 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $175.3 million in Q4 2024 and troughed at $101.0 million in Q2 2022.
  • The 5-year median for Total Liabilities is $116.3 million (2023), against an average of $125.4 million.
  • Year-over-year, Total Liabilities dropped 21.69% in 2022 and then surged 41.33% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $138.1 million in 2021, then dropped by 21.69% to $108.1 million in 2022, then grew by 14.67% to $124.0 million in 2023, then soared by 41.33% to $175.3 million in 2024, then decreased by 8.34% to $160.6 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Total Liabilities are $160.6 million (Q4 2025), $146.7 million (Q3 2025), and $147.2 million (Q2 2025).